Arrowhead Pharmaceuticals Inc (ARWR)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$62.70

Buy

$63.75

arrow-up$5.05 (+8.76%)

Prices updated at 31 Mar 2026, 12:35 EDT

Prices minimum 15 mins delay

Prices in USD

Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.

NASDAQ

3.83%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Christopher Anzalone,PhD

CEO

Dr. Christopher Anzalone,PhD

Most recent earnings

30 Sep 2025

Fiscal year end

30 Sep 2025

Employees

711

Head office

177 E Colorado Boulevard

Pasadena

United States

91105

+1 626 304-3400

ir@arrowheadpharma.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Douglas S. Ingram,Esq. Independent Director	0.06m
Dr. Michael S. Perry, PhD Independent Director	0.09m
Dr. Christopher Anzalone,PhD Chairman of the Board, Chief Executive Officer and President	0.98m
Dr. Mauro Ferrari, PhD Independent Director	0.08m
Dr. Adeoye Olukotun, M.D.,M.P.H. Independent Director	0.08m
Mr. Daniel Apel Chief Financial Officer and Principal Accounting Officer	0.23m
Mr. William D. Waddill Lead Independent Director	0.10m
Dr. Hongbo Lu, PhD Independent Director	0.08m
Ms. Victoria Vakiener Independent Director	0.08m
Mr. James Hamilton Chief of Discovery and Translational Medicine	0.62m
Mr. Patrick C. O'Brien Chief Operating Officer, General Counsel and Corporate Secretary	0.65m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	20,224,825
Vanguard Group Inc	15,293,121
BlackRock Fund Advisors	11,173,412
venBio Select Advisor LLC	10,625,000
FMR Inc	6,520,408

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2025	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
05 Jan 2026	-
31 Dec 2025	-
31 Dec 2025	-
31 Dec 2025	-
31 Dec 2025	-
29 Dec 2025	-
29 Dec 2025	-
29 Dec 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.